Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy
Medical guidance advises against prescribing it to patients already experiencing digestive symptoms like bloating and nausea given the potential for symptom exacerbation
This drug class offers significant benefits in reducing cardiovascular disease risk and improving renal function in T2DM patients
P values indicated, calculated by two-tailed t -test ( a,b,d ) or one-way ANOVA with Dunnetts multiple comparisons test ( g,i )
C., Gombart, A
Hypoglycemia Risk : In patients with diabetes, particularly those also taking insulin or sulfonylureas, tirzepatide can increase the risk of hypoglycemia, which manifests with fatigue, weakness, and other symptoms